Follow


Submissions from 2019

Link

Topical formulations to prevent sexually transmitted infections: Are we on track?, José Fernández-Romero, Maria Gabriela Paglini, and Thomas Zydowsky

Link

Understanding women’s motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence, Ariana Katz, Barbara Mensch, Kubashini Woeber, Petina Musara, Juliane Etima, and Ariane van der Straten

Link

Vaginal ring use in a phase 3 microbicide trial: A comparison of objective measures and self-reports of non-adherence in ASPIRE, Barbara Mensch, Barbara Richardson, Marla Husnik, Elizabeth R. Brown, Flavia Matovu Kiweewa, Ashley Mayo, Jared M. Baeten, Thesla Palanee-Phillips, Ariane van der Straten, and MTN-020-ASPIRE Study Team

Submissions from 2018

Link

Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo, Nina Derby, Manjari Lal, Meropi Aravantinou, Larisa Kizima, Patrick Barnable, Aixa Rodriguez, Manshun Lai, Asa Wesenberg, Shweta Ugaonkar, Keith Levendosky, Olga Mizenina, Kyle Kleinbeck, Jeffrey D. Lifson, M. Melissa Peet, Zachary Lloyd, Michael Benson, Walid Heneine, Barry R. O'Keefe, Melissa Robbiani, Elena Martinelli, Brooke Grasperge, James Blanchard, Agegnehu Gettie, Natalia Teleshova, José Fernández-Romero, and Thomas Zydowsky

Link

How presentation of drug detection results changed reports of product adherence in South Africa, Uganda and Zimbabwe, Petina Musara, Elizabeth T. Montgomery, Nyaradzo M. Mgodi, Kubashini Woeber, Carolyne Akello, Miriam Hartmann, Helen Cheng, Lisa Levy, Ariana Katz, Cynthia I. Grossman, Zvavahera M. Chirenje, Ariane van der Straten, Barbara Mensch, and Microbicide Trials Network-003D Study Team

Submissions from 2017

Link

An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques, Nina Derby, Meropi Aravantinou, Jessica Kenney, Shweta Ugaonkar, Asa Wesenberg, Jolanta Wilk, Larisa Kizima, Aixa Rodriguez, Shimin Zhang, Olga Mizenina, Keith Levendosky, Michael Cooney, Samantha Seidor, Agegnehu Gettie, Brooke Grasperge, James Blanchard, Michael Piatak Jr., Jeffrey D. Lifson, José Fernández-Romero, Thomas Zydowsky, and Melissa Robbiani

Link

Achieving the optimal vaginal state: Using vaginal products and study gels in Uganda, Zimbabwe, and South Africa, Zoe Duby, Barbara Mensch, Miriam Hartmann, Elizabeth T. Montgomery, Imelda Mahaka, Linda-Gail Bekker, and Ariane van der Straten

Link

MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1, Olga Mizenina, Mayla Hsu, Ninochka Jean-Pierre, Meropi Aravantinou, Keith Levendosky, Maria Gabriela Paglini, Thomas Zydowsky, Melissa Robbiani, and José Fernández-Romero

Link

Misreporting of product adherence in the MTN-003/VOICE trial for HIV prevention in Africa: Participants’ explanations for dishonesty, Elizabeth T. Montgomery, Barbara Mensch, Petina Musara, Miriam Hartmann, Kubashini Woeber, Juliane Etima, and Ariane van der Straten

Submissions from 2016

Link

A first-in-human trial of MIV-150 and zinc acetate co-formulated in a carrageenan gel: Safety, pharmacokinetics, acceptability, adherence and pharmacodynamics, Barbara Friedland, Craig Hoesley, Marlena Gehret Plagianos, Elena Hoskin, Shimin Zhang, Natalia Teleshova, Mohcine Alami, Lea Novak, Kyle Kleinbeck, Lauren L. Katzen, Thomas Zydowsky, José Fernández-Romero, and George W. Creasy

Link

In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel, Akiva P. Novetsky, Marla J. Keller, Ana Gradissimo, Zigui Chen, Stephanie L. Morgan, Xiaonan Xue, Howard D. Strickler, José Fernández-Romero, Robert Burk, and Mark H. Einstein

Link

A novel microbicide/contraceptive intravaginal ring protects macaque genital mucosa against SHIV-RT infection ex vivo, Guillermo Villegas, Giulia Calenda, Shweta Ugaonkar, Shimin Zhang, Larisa Kizima, Olga Mizenina, Agegnehu Gettie, James Blanchard, Michael Cooney, Melissa Robbiani, José Fernández-Romero, Thomas Zydowsky, and Natalia Teleshova

Link

In vitro exposure to PC-1005 and cervicovaginal lavages from women vaginally administered PC-1005 inhibit HIV-1 and HSV-2 infection in human cervical mucosa, Guillermo Villegas, Giulia Calenda, Shimin Zhang, Olga Mizenina, Kyle Kleinbeck, Michael Cooney, Craig Hoesley, George W. Creasy, Barbara Friedland, José Fernández-Romero, Thomas Zydowsky, and Natalia Teleshova

Submissions from 2015

PDF

Learning from women about HIV risk, HIV testing behaviors, and prevention practices in Mpumalanga, South Africa: A descriptive study to inform microbicides introduction, Martha Brady, Saiqa Mullick, Barbara Friedland, Marlena Gehret Plagianos, Linda Du Plessis, and Thabiso Mango

PDF

ARV-based HIV prevention for women: State of the science and considerations for implementation in Zimbabwe. Report from a provider workshop, Population Council

PDF

Introducing antiretroviral (ARV)-based prevention products for women: A guide to strategic decisionmaking and planning, Population Council

Submissions from 2014

PDF

Policy and programme considerations for ARV-based prevention for women: Insights from key opinion leaders in Zimbabwe about tenofovir gel, Samukeliso Dube, Barbara Friedland, Saiqa Mullick, Martha Brady, and C. Elizabeth McGrory

PDF

An overview of the HIV prevention landscape in Zimbabwe: Implications for tenofovir gel, Population Council

PDF

Program and policy considerations for tenofovir gel in India: An overview, Population Council

PDF

Setting the stage for ARV-based prevention for women: A snapshot of the Zimbabwean context, Population Council

Submissions from 2012

PDF

Shaping the operations research agenda for antiretroviral-based prevention products for women: Gels and rings, Martha Brady and C. Elizabeth McGrory

PDF

Nonclinical development needs and regulatory requirements for multipurpose prevention technologies: A primer, Joseph W. Romano, Martha Brady, and Judy Manning

Submissions from 2011

PDF

Constructing a critical path for product development, commercialization, and access, Martha Brady

PDF

Facilitating regulatory approval of multipurpose prevention technologies for sexual and reproductive health, Martha Brady

PDF

Day of dialogue on multipurpose prevention technologies: Toward clarity in nomenclature, Martha Brady and C. Elizabeth McGrory

PDF

What regulatory guidance exists for multipurpose prevention technologies (MPTs)? A review of key guidance documents and their applicability to MPTs, Martha Brady and Heeyoung Park

Submissions from 2008

PDF

Informed consent in HIV prevention trials: Highlights from an international workshop, Population Council

Submissions from 2007

PDF

Day of dialogue—Insights and evidence from product introduction: Lessons for microbicides, Martha Brady and C. Elizabeth McGrory

Submissions from 2006

PDF

Informed Consent in HIV Prevention Trials: Report of an International Workshop, C. Elizabeth McGrory, Barbara Friedland, Cynthia Woodsong, and Kathleen M. MacQueen

Submissions from 2003

PDF

Cultural norms and behavior regarding vaginal lubrication during sex: Implications for the acceptability of vaginal microbicides for the prevention of HIV/STIs, Sarah Braunstein and Janneke van de Wijgert

Submissions from 2002

PDF

Informed consent: From good intentions to sound practices—A report of a seminar, Susan Y. Wood, Barbara Friedland, and C. Elizabeth McGrory

Submissions from 2001

PDF

The case for microbicides: A global priority, Kathy Attawell

Submissions from 1998

PDF

A study of women's preferences regarding the formulation of over-the-counter vaginal spermicides, Christiana Coggins, Christopher J. Elias, Ronachai Atisook, Mary T. Bassett, Virginie Ettiegne-Traore, Peter D. Ghys, Laura Jenkins-Woelk, Earmporn Thongkrajai, and Nancy L. VanDevanter

Submissions from 1994

PDF

Partnership for prevention: A report of a meeting between women's health advocates, program planners, and scientists, Population Council